Literature DB >> 12788811

Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery.

O Pauvert1, C Lugnier, T Keravis, R Marthan, E Rousseau, J P Savineau.   

Abstract

(1) Sildenafil (viagra) is a potent PDE5 inhibitor and thus a relaxant drug in corpus carvernosum smooth muscle. In the present work, we evidenced the presence of PDE5 isozyme and investigated the effect of sildenafil on the specific cyclic nucleotide phosphodiesterase (PDE) activity, smooth muscle tone and calcium signaling in the rat main pulmonary artery (MPA). (2) The PDE activity was measured in cytosolic and microsomal fractions. Total cAMP and cGMP-PDE activities were mainly present in the cytosolic fraction. Sildenafil (0.1 micro M) reduced by 72% cGMP-PDE activity, whereas zaprinast (10 micro M), a relatively selective PDE5 inhibitor, reduced this activity by 63%. Sildenafil (0.1 micro M) also inhibited significantly (22%) the cAMP-PDE activity. (3) Western blot analysis revealed the expression of PDE5 mainly in the cytosolic fraction of MPA. Sildenafil concentration-dependently inhibited (IC(50)=3.4 nM) the activity of MPA PDE5 partially purified by HPLC. (4) Sildenafil (0.1 nM-50 micro M) concentration-dependently relaxed MPA rings precontracted with phenylephrine (0.5 micro M). The potency of sildenafil (IC(50)=11 nM) was similar to that of a nitric oxide donor, sodium nitroprusside, but higher than that of zaprinast (IC(50)=600 nM). The vasorelaxant effect of sildenafil was not altered by endothelium removal or in the presence of KT 5823 (1 micro M) and H89 (1 micro M), potent inhibitors of PKG and PKA, respectively. (5) In isolated MPA myocytes, which had been loaded with the calcium fluorophore indo-1, sildenafil (10-100 nM) antagonized ATP- and endothelin-1-induced calcium oscillations but had no effect on the transient caffeine-induced [Ca(2+)](i) response. (6) This study demonstrates the presence of a functional and highly sildenafil-sensitive PDE5 isozyme in rat MPA. Inhibition of this isozyme mainly accounts for the potent pulmonary vasodilator action of sildenafil, which involves alteration in the inositol triphosphate-mediated calcium signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12788811      PMCID: PMC1573876          DOI: 10.1038/sj.bjp.0705277

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

Review 1.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.

Authors:  S H Soderling; J A Beavo
Journal:  Curr Opin Cell Biol       Date:  2000-04       Impact factor: 8.382

2.  Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessel.

Authors:  C Lugnier; T Keravis; A Eckly-Michel
Journal:  J Physiol Pharmacol       Date:  1999-12       Impact factor: 3.011

Review 3.  Pathophysiology and clinical effects of chronic hypoxia.

Authors:  D J Pierson
Journal:  Respir Care       Date:  2000-01       Impact factor: 2.258

4.  Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension.

Authors:  D Abrams; I Schulze-Neick; A G Magee
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

5.  Sildenafil inhibits hypoxia-induced pulmonary hypertension.

Authors:  L Zhao; N A Mason; N W Morrell; B Kojonazarov; A Sadykov; A Maripov; M M Mirrakhimov; A Aldashev; M R Wilkins
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

6.  Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery.

Authors:  O Pauvert; D Salvail; E Rousseau; C Lugnier; R Marthan; J P Savineau
Journal:  Biochem Pharmacol       Date:  2002-05-01       Impact factor: 5.858

7.  Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension.

Authors:  F Ichinose; J Erana-Garcia; J Hromi; Y Raveh; R Jones; L Krim; M W Clark; J D Winkler; K D Bloch; W M Zapol
Journal:  Crit Care Med       Date:  2001-05       Impact factor: 7.598

Review 8.  Molecular mechanism of cGMP-mediated smooth muscle relaxation.

Authors:  J A Carvajal; A M Germain; J P Huidobro-Toro; C P Weiner
Journal:  J Cell Physiol       Date:  2000-09       Impact factor: 6.384

Review 9.  Cyclic nucleotide phosphodiesterases: relating structure and function.

Authors:  S H Francis; I V Turko; J D Corbin
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2001

10.  NO-induced modulation of calcium-oscillations in pulmonary vascular smooth muscle.

Authors:  O Pauvert; R Marthan; J Savineau
Journal:  Cell Calcium       Date:  2000-06       Impact factor: 6.817

View more
  13 in total

1.  Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design.

Authors:  Gregor Bender; James Gosset; Jeff Florian; Keith Tan; Mark Field; Scott Marshall; Joost DeJongh; Robert Bies; Meindert Danhof
Journal:  Pharm Res       Date:  2009-08-11       Impact factor: 4.200

2.  Phosphodiesterase-5A (PDE5A) is localized to the endothelial caveolae and modulates NOS3 activity.

Authors:  Milena A Gebska; Blake K Stevenson; Anna R Hemnes; Trinity J Bivalacqua; Azeb Haile; Geoffrey G Hesketh; Christopher I Murray; Ari L Zaiman; Marc K Halushka; Nispa Krongkaew; Travis D Strong; Carol A Cooke; Hazim El-Haddad; Rubin M Tuder; Dan E Berkowitz; Hunter C Champion
Journal:  Cardiovasc Res       Date:  2011-03-18       Impact factor: 10.787

3.  Phosphodiesterase 5 inhibition attenuates cerebral vasospasm and improves functional recovery after experimental subarachnoid hemorrhage.

Authors:  Byung Hee Han; Ananth Kesav Vellimana; Meng-Liang Zhou; Eric Milner; Gregory Joseph Zipfel
Journal:  Neurosurgery       Date:  2012-01       Impact factor: 4.654

4.  Sildenafil inhibits chronically hypoxic upregulation of canonical transient receptor potential expression in rat pulmonary arterial smooth muscle.

Authors:  Wenju Lu; Pixin Ran; Dandan Zhang; Gongyong Peng; Bing Li; Nanshan Zhong; Jian Wang
Journal:  Am J Physiol Cell Physiol       Date:  2009-11-04       Impact factor: 4.249

5.  Caffeine inhibits InsP3 responses and capacitative calcium entry in canine pulmonary arterial smooth muscle cells.

Authors:  Joseph R Hume; Claire E McAllister; Sean M Wilson
Journal:  Vascul Pharmacol       Date:  2008-11-21       Impact factor: 5.773

6.  PDEs1-5 activity and expression in tissues of cirrhotic rats reveal a role for aortic PDE3 in NO desensitization.

Authors:  Rima Tahseldar-Roumieh; Thérèse Keravis; Suha Maarouf; Hélène Justiniano; Ramzi Sabra; Claire Lugnier
Journal:  Int J Exp Pathol       Date:  2009-09-15       Impact factor: 1.925

Review 7.  Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications.

Authors:  Praneet Kumar; Gary S Francis; W H Wilson Tang
Journal:  Nat Rev Cardiol       Date:  2009-05       Impact factor: 32.419

Review 8.  Sildenafil in the treatment of pulmonary hypertension.

Authors:  Christopher F Barnett; Roberto F Machado
Journal:  Vasc Health Risk Manag       Date:  2006

Review 9.  Vasodilator compounds derived from plants and their mechanisms of action.

Authors:  Francisco J Luna-Vázquez; César Ibarra-Alvarado; Alejandra Rojas-Molina; Isela Rojas-Molina; Miguel Angel Zavala-Sánchez
Journal:  Molecules       Date:  2013-05-17       Impact factor: 4.411

10.  An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants.

Authors:  N Thakkar; D Gonzalez; M Cohen-Wolkowiez; M M Massaro; J Bernhardt; N R Zane; M M Laughon
Journal:  J Perinatol       Date:  2016-05-12       Impact factor: 3.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.